Stoke Therapeutics Stock Price, News & Analysis

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA-based medicines, will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:00 a.m. ET. The presentation will be in a fireside chat format, available via live webcast on Stoke's website. Stoke aims to address severe diseases by upregulating protein expression using its proprietary TANGO approach. Their lead compound, STK-001, is in clinical testing for Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.

Stoke Therapeutics, Inc. (Nasdaq: STOK) reported a net loss of $85.8 million for 2021, reflecting an increase in research and development expenses to $54.2 million. The company continues to advance its clinical pipeline, including ongoing Phase 1/2a studies for STK-001 in treating Dravet syndrome and preclinical studies for STK-002 targeting Autosomal Dominant Optic Atrophy (ADOA). With $220.4 million in cash and a recent $60 million collaboration with Acadia Pharmaceuticals, Stoke is positioned to fund operations through mid-2024 and share additional clinical data in 2H 2022.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm focused on RNA-based therapies for severe diseases, will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via a live webcast on their official website, with a replay available for 30 days. Stoke utilizes its innovative TANGO approach to develop targeted treatments, such as STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy. The company is headquartered in Bedford, Massachusetts.

Ceptur Therapeutics, a biotechnology company focused on U1 Adaptor technology, has successfully completed a $75M Series A financing round. The round was co-led by venBio Partners and Qiming Venture Partners USA, with participation from various investors including Bristol Myers Squibb and Janus Henderson Investors. The funds will be used to advance their genetic medicine pipeline. Ceptur's U1 Adaptors aim to regulate gene expression at the pre-mRNA level, offering innovative therapeutic applications for genetic diseases.

Acadia Pharmaceuticals and Stoke Therapeutics have formed a collaboration to co-develop RNA-based therapies for severe neurodevelopmental diseases, including SYNGAP1 syndrome and Rett syndrome. Acadia gains exclusive licenses for two additional preclinical programs. Stoke receives a $60 million upfront payment, with potential milestone payments reaching $907 million, along with royalties. The partnership combines Stoke’s TANGO research platform with Acadia’s development expertise, aiming to enhance treatment options for patients with these debilitating conditions.

Stoke Therapeutics, Inc. (NASDAQ: STOK) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. The conference will feature a live audio webcast available on the company's investor relations website, along with a replay accessible for 30 days post-event. Stoke focuses on developing RNA-based medicines to address severe diseases by upregulating protein expression, with its lead compound STK-001 currently in clinical testing for Dravet syndrome.

Stoke Therapeutics (NASDAQ: STOK) presented promising data regarding its investigational therapy STK-001 for Dravet syndrome at the American Epilepsy Society 2021 Annual Meeting. Single doses of STK-001 (up to 30 mg) and multiple doses (20 mg) were well tolerated. Notably, 70.6% of patients displayed reduced convulsive seizure frequency within 84 days post-treatment. All patients aged 2-12 experienced a reduction in seizure frequency, and further data on pharmacokinetics and safety will be released. Stoke aims to target the underlying genetic causes of Dravet syndrome, representing a potential breakthrough in treatment.

Stoke Therapeutics (NASDAQ: STOK) announced that five abstracts regarding STK-001 for treating Dravet syndrome will be presented at the American Epilepsy Society annual meeting from December 3-7, 2021 in Chicago. The presentations include interim data on safety, pharmacokinetics, and exposure from the Phase 1/2a MONARCH study. Stoke aims to develop the first disease-modifying therapy for Dravet syndrome, a severe genetic epilepsy with no approved therapies. Updates from the ongoing studies will provide insights into treatment efficacy and safety.

Stoke Therapeutics, Inc. (Nasdaq: STOK) has nominated STK-002 as a clinical candidate targeting autosomal dominant optic atrophy (ADOA), an inherited optic nerve disorder. The company reported financial results for Q3 2021, showing a net loss of $22.6 million, or $0.61 per share, compared to $13.7 million, or $0.41 per share in 2020. Research and development expenses rose to $14.4 million from $8.1 million year-over-year. With $236.9 million in cash as of September 30, 2021, Stoke expects to fund operations through 2023. Positive interim data from the MONARCH study of STK-001 was also highlighted.